Roche AG, of Basel, Switzerland, said Gazyvaro (obinutuzumab) was approved in Europe in combination with chlorambucil chemotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia who have comorbidities making them unsuitable for an intensive therapy (full-dose fludarabine based therapy).